A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
A Phase I/IIa, double-blind, placebo-controlled, randomised study designed to evaluate the
safety, tolerability, exploratory efficacy and exposure of LTX-109 administered topically to
the anterior nares in subjects with persistent carriage of S. aureus (methicillin-susceptible
S. aureus [MSSA] and/or methicillin-resistant S. aureus [MRSA]).